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Ephedrine and herbal ephedra preparations have been shown to induce a small-to-moderate weight loss. Owing
to reports on serious cardiovascular events, they were banned from the US market in 2004. There have been no
large controlled studies on the possible association between prescribed ephedrine/caffeine and cardiovascular
events in general. The authors linked data from four different sources within Statistics Denmark, using data on
257,364 users of prescribed ephedrine/caffeine for the period 1995–2002. The data were analyzed using a case-
crossover technique with a composite endpoint: death outside of a hospital, myocardial infarction, or stroke. To
account for effects of chronic exposure and effects in naı ¨ve users, the authors performed a secondary case-control
study nested within the cohort of ephedrine/caffeine ever users. Among 2,316 case subjects, 282 (12.2%) were
current users of ephedrine/caffeine. The case-crossover analysis yielded an odds ratio of 0.84 (95% conﬁdence
interval: 0.71, 1.00); after adjustment for trends in ephedrine/caffeine use, it was 0.95 (95% conﬁdence interval:
0.79, 1.16). Subgroup analyses revealed no strata with signiﬁcantly elevated risk. In the case-control substudy,
there was no increased risk among naı ¨ve users or users with large cumulative doses. Prescribed ephedrine/
caffeine was not associated with a substantially increased risk of adverse cardiovascular outcomes in this study.
Ephedra sinica; ephedrine; mortality; myocardial infarction; stroke
Abbreviations: CI, conﬁdence interval; ICD, International Classiﬁcation of Diseases; OR, odds ratio.
Ephedrine is a sympathomimetic compound with lipolytic
and appetite-inhibiting properties (1). It is an alkaloid extract
from ephedra shrubs growing in Asia, Europe, and America.
The Asian species (Ephedra sinica) has the highest alkaloid
content, and it has been used in traditional folk remedies (ma
huang),particularlyinChina (2).InWesterncountries,ephed-
rine has been used to promote weight loss and to enhance
athletic performance (1). During the 1990s, it was found that
nearly one-third of young, obese women had used a weight-
loss supplement containing ephedra (3). In 1999 alone, 12
million persons in the United States used 3 billion doses of
ephedra alkaloids (3). The US Food and Drug Administration
bannedthesaleofephedrinein2004becauseofaconsiderable
number of reports of adverse vascular complications (4).
The suspicion of cardiovascular toxicity of ephedrine was
mainly based on spontaneous reporting (2, 3, 5). There were
no large-scale controlled observational studies conducted to
broadly assess the cardiovascular toxicity of ephedrine. Until
2002, a prescribed ephedrine preparation, Letigen (Nycomed
International Management GmbH, Zurich, Switzerland), had
a dominant position in the Danish market for weight-loss
products. The existence of a national prescription database
with comprehensive recording of all prescriptions ﬁlled in
Denmark since 1995, with the possibility of linkage to a wide
array of other health databases (6), offered us a unique op-
portunity to address the question of ephedrine’s cardiovascu-
lar toxicity in a controlled observational study.
MATERIALS AND METHODS
Use of prescribed ephedrine in Denmark
Letigen was a pharmaceutical product containing 20 mg
of synthetic ephedrine and 200 mg of caffeine, available
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per day, depending on the user’s tolerance. It was approved
for sale in Denmark in 1990. During the peak of its use in
1999, some 110,000 persons, corresponding to 2% of the
Danish population, were treated (7). In 2002, the marketing
license was suspended, after a number of reports had sug-
gested a safety problem.
Data sources
We used data from Statistics Denmark, a governmental
institution that collects and maintains electronic records for
statistical and scientiﬁc purposes. Four comprehensive na-
tional data sources were used: the Danish National Registry
of Patients, the Prescription Database of the Danish Medi-
cines Agency, the Danish Register of Death, and the Danish
Person Registry. All data sources were linked by use of
a mutual identiﬁer.
Since 1977, data on all individual hospital discharges
have been stored in the Danish National Registry of Pa-
tients. Each record contains an identiﬁer as well as selected
medical data, including discharge diagnoses and operative
procedures. Diagnoses were recorded according to the In-
ternational Classiﬁcation of Diseases, Eighth Revision
(ICD-8), from 1977 through 1993 and have been recorded
according to the International Classiﬁcation of Diseases,
Tenth Revision (ICD-10), since 1994. Virtually all inpatient
medical care in Denmark during the study period (1995–
2001) was furnished by the public health authorities; thus,
this data resource allows true population-based studies,
covering all 5.4 million inhabitants of Denmark (8).
The Prescription Database of the Danish Medicines
AgencycontainsdataonallprescriptionsredeemedbyDanish
citizens since 1995, independently of whether or not the cost
of the medication was reimbursed. Among the data included
are a person identiﬁer, the date of purchase, a prescriber code,
the substance, the brand name, and the quantity dispensed.
Dosing instructions and the indication for prescribing the
medication are not recorded. Drugs are categorized according
to the Anatomic-Therapeutic-Chemical classiﬁcation (9).
TheDanish RegisterofDeath containsinformation on date
of death, cause of death, and mode of death (natural cause,
accident,suicide,orhomicide)andacodeindicatingtheloca-
tion where the death occurred (in a hospital, at another health
institution, at home, or elsewhere). The Danish Person Regis-
try contains data on all migrations into and out of Denmark,
whichallowedustokeeptrackofallephedrine/caffeineusers.
The base population for this study was all persons who
had ﬁlled prescriptions for ephedrine/caffeine during the
period January 1, 1995–December 31, 2001. For this cohort
of 298,848 persons, we extracted data on all prescriptions
for cardiovascular, antithrombotic, antidiabetic, antirheu-
matic, antiasthmatic, and appetite-suppressant medications
ﬁlled during the same period, and from the other registers,
we obtained all available information on the subjects.
Analysis
Design. For our primary analysis, we used the case-
crossover design. It is based on the case-base paradigm,
but instead of the use of matched controls, the past experi-
ence of the case serves as the case’s own reference. Thereby,
confounders that are stable over time cancel each other out.
This even extends to stable confounders that cannot be mea-
sured or are unknown (10–12). In the present context, use of
ephedrine/caffeine could have been related to smoking and
obesity (13). Case-crossover designs are particularly suit-
able when the exposure is intermittent, the effect on risk is
immediate and transient, and the outcome is abrupt (10).
The available reports suggested that the potential cardiovas-
cular toxicity would indeed be immediate and transient and
that the outcome would be abrupt (2, 3, 5).
Certain aspects of our research question were not amenable
to a case-crossover study. Some spontaneous reports had sug-
gested a particular risk in naı ¨ve, ﬁrst-time users (3). Since
subjects could not be naı ¨ve users both on their case date and
on their control date, this would violate the conditions for
a crossover study. We alsowanted to study the effectof chronic
exposure, for which the crossover type of study is inefﬁcient
(11). Finally, we wanted to explore a possible cumulative dose
effect, for which the crossover design would not work (highest
cumulative dose on the reference date would be impossible).
To address these issues, we conducted a supplementary case-
control study. To minimize potential confounding by indica-
tion, we nested the case-control study within a cohort of ever
users of ephedrine/caffeine as described below.
Study cohort deﬁnition. Both the case-crossoverstudy and
the case-control study were nested within a cohort of ever
users of ephedrine/caffeine. Persons entered the cohort and
were eligible to become cases whenall ofthefollowing events
had occurred: 1) the start of the study period on July 1, 1996;
2) January 1 of the year of the subject’s 18th birthday; 3) the
ﬁlling of the ﬁrst recorded ephedrine/caffeine prescription;
and 4) residence in Denmark for at least 18 months. Thus,
we required all subjects to have been observable for any med-
ication dispensation for at least 18 months and to have ﬁlled at
least one prescription for ephedrine/caffeine.
The subjects left the cohort at the ﬁrst occurrence of one
of the following: 1) any case-deﬁning event; 2) death or
emigration; 3) January 1 of the year of the subject’s 70th
birthday; 4) any diagnosis of malignancy, excluding non-
melanoma skin cancer (ICD-10 codes C00–C97, excluding
code C44; ICD-8 codes 140–207, excluding code 173); and
5) the end of study period on December 31, 2001.
We excluded persons who underwent one of the cohort-
terminating events (e.g., a cancer diagnosis or emigration)
before their potential cohort entry and persons who had
more than one migration event.
Case deﬁnition. Since the literature on adverse effects of
ephedrine is ambiguous about what particular cardiovascu-
lar effects to expect (2–5), we employed a broad, composite
primary endpoint and performed secondary analyses on
each subset of this endpoint.
Our primary endpoint was deﬁned by the occurrence of
any of the following:
  Death coded as due to natural causes, occurring outside of
a hospital or nursing home.
  Myocardial infarction, deﬁned by hospitalization with
a discharge diagnosis of myocardial infarction (ICD-10
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at least 3 days in duration, unless the patient died within
the ﬁrst 3days of admission. Toaccount for hospital trans-
fers for invasive procedures or other specialist treatment,
serial admissions with no discharge interval between them
were considered a single admission. Fatal myocardial in-
farction was deﬁned as the patient’s dying within 30 days
after the index hospitalization.
  Stroke, deﬁned by hospitalization with an ICD-10 dis-
charge code of I61, I63, or I64, excluding codes I63.1
and I63.4 (cerebral embolism). Duration-of-stay and
case-fatality criteria similar to those for the myocardial
infarction cases were applied.
Exposure deﬁnition. We computed the frequency distri-
butions of intervals between presentations of prescriptions
for ephedrine/caffeine. On the basis of these analyses, we
estimated the modal intake as slightly less than 2 tablets per
day (14). Very few users had taken 4 or more tablets per day
for extended periods of time. In our main analysis, we as-
signed a period of exposure for each prescription, starting on
the day of prescription redemption and assuming a daily
intake of 2 tablets, until all tablets were taken. Subjects were
considered exposed on all days within a prescription’s sup-
ply period and unexposed on all other days. As a sensitivity
analysis, we repeated all analyses with an assumed daily
intake of 1 or 3 tablets and with a ﬁxed 90-day exposure
period assigned to each prescription.
Our exploratory analyses conﬁrmed the episodic nature of
ephedrine/caffeine therapy. Using a waiting-time-distribution
technique (14), we arrived at an average duration varying
between 8.8 months and 13 months for the period 1995–
2001. For other medications included as time-dependent
covariates, we employed a ﬁxed 90-day window to deﬁne
exposure; that is, a person was considered exposed to aspirin
if he or she had ﬁlled a prescription for aspirin within the
past 90 days.
Case-crossover study. In the case-crossover design, a
patient’s exposure status at the time of disease is compared
with the same patient’s individual exposure at an earlier
point in time. For each case subject, 10 control dates were
assigned randomly within the period 9–15 months before
the case date for the same individual. For cases that arose
shortly after cohort entry, this entailed sampling control
dates before cohort entry. We chose these control dates be-
cause of the seasonality in ephedrine/caffeine use. For ex-
ample,therewere approximately twice as manynew users in
January as in December and a small excess of use in the
early summer months.
Time-dependent potential confounders were controlled
by conditional logistic regression (10). We included use
of low-dose aspirin, statins, antihypertensive agents, anti-
diabetic agents, and nonsteroidal antiinﬂammatory drugs
as time-dependent covariates in all analyses. We also con-
ducted analyses without inclusion of these covariates,
but results are not presented, since they differed very little
from those of the main analysis. We calculated odds ratios
for our main endpoint, for each subset of endpoints, and for
a number of prespeciﬁed patient subgroups as detailed in
the tables.
Adjustment for trends in exposure. Therewas a moderate
decline in ephedrine/caffeine use during the last part of the
study period, and the prevalence of ephedrine/caffeine use
declined rapidly with age for persons aged 55 years or
older (7). This would convey a spurious protective effect
of ephedrine/caffeine; cases were less likely to use ephedrine/
caffeine on their case date than on their control date, since
they were approximately 1 year older and possibly had en-
tered a period of lower ephedrine/caffeine use in general.
To adjust for this, Suissa (15) proposed the case-time-
control design. A matched control group is extracted, and
their exposure attributes on the index day and on a control
date in the past are established in exactly the same ways as
for the cases. Control subjects are then used as a reference
group for the odds ratio derived from the case-crossover
study (15). For each subject, we used 4 random controls
selected as described below.
Case-control study. In the case-control substudy, we
used the same cases and the same exposure deﬁnition as
in the case-crossover study. For each case, we randomly
selected 10 control subjects matched to the casewith respect
Table 1. Characteristics of all users and of those experiencing
a case-deﬁning event
a among 257,364 users of a ﬁxed-dose
caffeine/ephedrine product, Denmark, 1995–2001
All Ephedrine/
Caffeine Users
(n 5 257,364)
Cases
(n 5 2,316)
No. % No. %
Person-years of follow-up 1,023,297 5,534
Men 51,974 20.2 1,019 44.0
Median age, years 36 (28–48)
b 55 (47–61)
Secondary endpoints
Death outside hospital 531 22.9
Myocardial infarction 839 36.2
Fatal myocardial infarction 55 2.4
Stroke 946 40.8
Fatal stroke 58 2.5
Prior diagnosis of:
Obesity 11,389 4.4 264 11.4
Diabetes 6,518 2.5 264 11.4
Hypertension 26,391 10.3 245 10.6
Chronic obstructive
pulmonary disease 3,515 1.4 187 8.1
Ischemic heart disease 5,329 2.1 327 14.1
Cerebrovascular disease 1,414 0.5 146 6.3
Prior use of:
Acetylsalicylic acid 6,884 2.7 348 15.0
Antihypertensive agents 57,521 22.4 1,178 50.9
Statins 5,587 2.2 195 8.4
Antidiabetic agents 6,935 2.7 283 12.2
a Death outside of a hospital, myocardial infarction, or stroke.
b Numbers in parentheses, interquartile range.
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in the cohort on the index date. Controls were assigned
an index date identical to that of the case date of the cor-
responding case. Since we sampled controls from our
study cohort, the reference category for comparison of cur-
rent ephedrine/caffeine exposure was remote use of the
medication.
In the case-control study, we placed a special focus on
potential dose-response and duration-response effects. We
used the number of tablets purchased within the last 90 days
before the index date as a measure of current dose and the
cumulative amount of ephedrine/caffeine ever recorded up
to the index date as a measure of cumulative dose. For the
duration-response effect, we categorized subjects according
to the time of the ﬁrst recorded prescription relative to the
index date.
The following variables were included as potential con-
founders: 1) ever diagnosis of obesity (ICD-10 code E66;
ICD-8 code 27799); 2) ever use of antidiabetic agents or
a diagnosis of diabetes (ICD-10 codes E10–E14; ICD-8
code 250); 3) current use of low-dose acetylsalicylic acid;
4) ever diagnosis of chronic obstructive pulmonary disease
(ICD-10 code J44; ICD-8 codes 490–491) or ever use of
systemic beta-agonists or inhaled anticholinergic agents;
5) ever diagnosis of hypertension (ICD-10 code I10; ICD-8
code 40) or ever use of antihypertensive agents (i.e., thia-
zides, beta-blockers, calcium channel blockers, and medi-
cations acting on the renin-angiotensin system); 6) ever use
of statins; 7) ever diagnosis of ischemic heart disease or
myocardial infarction (ICD-10 codes I20–I25; ICD-8 codes
412–414); and 8) ever diagnosis of cerebral ischemia or
stroke (ICD-10 codes I61, I63, and I64, excluding codes
I631 and 641; ICD-8 codes 431 and 433–435). Confounders
were controlled by conditional logistic regression.
For all estimates, we report 95% conﬁdence intervals.
The study was approved by Statistics Denmark’s scien-
tiﬁc board. Approval from an ethics committee was not re-
quired according to Danish law. Data were analyzed using
Stata, version 8.0 (Stata Corporation, College Station, Texas).
RESULTS
Study cohort
Of the 298,848 persons registered as using ephedrine/
caffeine,41,484 did not enter the study cohort, for the follow-
ing reasons: 1) the subject was outside the allowed age range
of 18–70 years throughout the study period (n ¼ 11,347);
2) a cancer diagnosis or other cohort-terminating event pre-
ceded potential cohort entry (n ¼ 25,395); and 3) more than
one migration event was recorded (n ¼ 4,445) or the subject
immigrated too late to be observable for 18 months (n ¼ 297).
In all, 257,364 users of ephedrine/caffeine (51,974 men and
205,390 women) entered the cohort. They contributed
1,023,297 person-years of observation, during which
2,316 case-deﬁning events occurred. Their clinical charac-
teristics are detailed in Table 1.
Case-crossover study
Of the 2,316 cases, 531 were deaths that occurred outside
of a hospital, 839 were myocardial infarctions, and 946 were
strokes. The characteristics of the case subjects are listed in
Table 1. Their median age was 55 years, and 1,019 (44%)
Table 2. Main results from a case-crossover analysis of the association between use of
prescribed ephedrine/caffeine and cardiovascular morbidity, Denmark, 1995–2001
a
Endpoint
Cases
Case-Crossover
Estimate
b
Case-Time-Control
Estimate
c
Total
No.
Exposed to
Ephedrine/
Caffeine
No. % AOR 95% CI AOR 95% CI
Main composite endpoint
d 2,316 282 12.2 0.84 0.71, 1.00 0.95 0.79, 1.16
Secondary endpoints
Death outsideof a hospital 531 50 9.4 0.53 0.36, 0.79 0.54 0.35, 0.84
Myocardial infarction 839 109 13.0 0.94 0.71, 1.25 1.14 0.83, 1.56
Fatal myocardial infarction 55 6 10.9 0.53 0.16, 1.71 1.43 0.40, 5.14
Stroke 946 123 13.0 0.95 0.73, 1.23 1.07 0.80, 1.43
Fatal stroke 58 7 12.1 0.46 0.17, 1.27 0.92 0.29, 2.87
Abbreviations: AOR, adjusted odds ratio; CI, conﬁdence interval.
a The analysis was based on the assumption of an intake of 2 tablets per day starting from the
day on which the prescription was ﬁlled. For each case subject, 10 random control days were
sampled within the interval of 9–15 months prior to the index date.
b Adjusted for discordant use of aspirin, statins, antihypertensive agents, antidiabetic agents,
and nonsteroidal antiinﬂammatory drugs by conditional logistic regression.
c Adjusted for discordant use of aspirin, statins, antihypertensive agents, antidiabetic agents,
and nonsteroidal antiinﬂammatory drugs and for trend in ephedrine/caffeine prescriptions.
d Death outside of a hospital, myocardial infarction, or stroke.
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more prevalent among cases than among users of ephedrine
in general; 50.9% had a history of antihypertensive use,
15.0% of acetylsalicylic acid use, and 12.2% of anti-
diabetic use. Of the cases, 282 (12.2%) were current users
of ephedrine/caffeine, the remaining being past users.
Among the 2,316 cases, 824 (36%) showed some degree
of discordant exposure—that is, they were either exposed on
the case date and unexposed on one or more of the reference
dates or they were unexposed on the case date and exposed
on at least one reference date. The odds ratio associating
ephedrine/caffeine use with an adverse cardiovascular out-
come, adjusted for discordant use of other cardiovascular
medications and antidiabetic agents, was 0.84 (95% conﬁ-
dence interval (CI): 0.71, 1.00). Further adjustment for trend
in ephedrine prescriptions yielded an odds ratio of 0.95 (95%
CI: 0.79, 1.16). The odds ratios for sub-endpoints are shown
in Table 2. For death occurring outside of a hospital, there
was an inverse association with current ephedrine use (ad-
justed odds ratio (OR) ¼ 0.54, 95% CI: 0.35, 0.84).
The explorative analyses revealed no subjects whose odds
ratios were substantially elevated above the main group
(Table 3). For women and for users of statins, an inverse
association was observed (OR ¼ 0.76 (95% CI: 0.59, 0.99)
and OR ¼ 0.42 (95% CI: 0.18, 0.93), respectively). The
95% conﬁdence intervals for all other estimates spanned
the null value.
The sensitivity analyses assuming a daily intake of 1 or
3 tablets or assigning a ﬁxed 90-day window to each ephed-
rine prescription produced odds ratios of the same magni-
tude as those seen in the main analysis. The odds ratios for
the main estimate were 1.20 (95% CI: 1.00, 1.43), 0.90
(95% CI: 0.73, 1.10), and 1.08 (95% CI: 0.90, 1.29),
respectively.
Case-control study
In the case-control substudy, an odds ratio of 1.23 (95%
CI: 0.67, 2.27) was found for the subgroup whose ﬁrst
ephedrine prescription was ﬁlled 0–10 days before the index
Table 3. Results from subgroup analysis in a case-crossover study of the association between use of prescribed
ephedrine/caffeine and cardiovascular morbidity, Denmark, 1995–2001
a
Subgroup No. of
Cases
No. of
Exposed
Cases
Case-Crossover
Estimate
b
Case-Time-Control
Estimate
c
AOR 95% CI AOR 95% CI
Total 2,316 282 0.84 0.71, 1.00 0.95 0.79, 1.16
Sex
Men 1,019 132 1.06 0.82, 1.37 1.28 0.96, 1.71
Women 1,297 150 0.70 0.56, 0.88 0.76 0.59, 0.99
Age group, years
 39 199 27 1.04 0.60, 1.81 1.10 0.59, 2.03
40–59 1,182 152 0.95 0.75, 1.20 0.99 0.76, 1.29
 60 935 103 0.67 0.50, 0.89 0.90 0.65, 1.24
Prior diagnosis of diabetes or use of
antidiabetic agents 355 45 0.84 0.53, 1.33 1.19 0.67, 2.09
Prior diagnosis of ischemic heart disease 327 27 0.55 0.33, 0.92 0.79 0.41, 1.51
Prior diagnosis of chronic obstructive
pulmonary disease or use of inhaled
anticholinergic agents 329 47 1.05 0.68, 1.61 1.29 0.75, 2.23
Prior diagnosis of cerebrovascular disease 146 30 2.49 1.38, 4.51 1.40 0.57, 3.42
Prior use of statins 195 15 0.40 0.20, 0.80 0.42 0.18, 0.93
Prior diagnosis of hypertension or use of
antihypertensive agents 1,259 150 0.80 0.63, 1.01 1.07 0.81, 1.40
Prior diagnosis of obesity 264 32 1.09 0.65, 1.84 1.82 0.96, 3.45
No cardiovascular antecedents
d 844 102 0.81 0.61, 1.08 0.84 0.62, 1.14
Abbreviations: AOR, adjusted odds ratio; CI, conﬁdence interval.
a The analysis was based on the assumption of an intake of 2 tablets per day starting from the day on which the
prescription was ﬁlled. For each case subject, 10 random control days were sampled within the interval of 9–15
months prior to the index date. The main composite endpoint was employed for all analyses (see Table 2).
b Adjusted for discordant use of aspirin, statins, antihypertensive agents, antidiabetic agents, and nonsteroidal
antiinﬂammatory drugs by conditional logistic regression.
c Adjusted for discordant use of aspirin, statins, antihypertensive agents, antidiabetic agents, and nonsteroidal
antiinﬂammatory drugs and for trend in ephedrine/caffeine prescriptions.
d No prior cardiovascular diagnoses or use of cardiovascular, antidiabetic, antithrombotic, or antihypertensive
medications.
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ing duration since the ﬁrst ephedrine/caffeine prescription
(for each successive step, OR ¼ 0.89, 95% CI: 0.82, 0.97).
We found no indication of a trend with lifetime cumulative
dose(perstep,OR ¼ 0.93,95%CI:0.85,1.01)orcumulative
dose within the past 90 days (per step, OR ¼ 0.95, 95%
CI: 0.81, 1.10).
In the case-control substudy, the adjusted odds ratios for
the main composite endpoint, for death outside a hospital,
for myocardial infarction, and for stroke were 0.88 (95% CI:
0.77, 1.01), 0.76 (95% CI: 0.54, 1.07), 0.95 (95% CI: 0.76,
1.18), and 0.92 (95% CI: 0.75, 1.13), respectively (data not
shown).
DISCUSSION
Our main ﬁnding was that prescription of an ephedrine/
caffeine product was not associated with adverse cardiovas-
cular outcomes. This was found across a wide range of
patient subgroups, different cardiovascular outcomes, dif-
ferent assumptions about exposure, and different utilization
patterns.
The strength of our study is the comprehensive recording
of clinical details for a very large population with virtually
no loss to follow-up. One limitation of our study is that it
concerned a pharmaceutical ephedrine preparation, pro-
duced under strict control. Findings may not be applicable
to herbal products whose content of ephedra alkaloids varies
substantially (16). In addition, herbal products may be used
under less appropriate instruction or surveillance.
The evidence linkingephedrine to cardiovascular morbid-
ity is based mainly on spontaneous reporting. However, with
the very large number of users (3) and their possible adverse
health behavior (13), coincidental cardiovascular events
probably occur in large numbers.
There have been only a few controlled observational stud-
ies on ephedra alkaloids and cardiovascular outcomes. In the
Hemorrhagic Stroke Project, an association was found be-
tween phenylpropanolamine and hemorrhagic stroke (17).
Phenylpropanolamine is a minor metabolite of ephedrine
which, in its synthetic form, is used as a cold remedy and
Table 4. Results from explorative dose-response and dose-duration analyses in a case-control study of the association between use of
prescribed ephedrine/caffeine and cardiovascular morbidity, Denmark, 1995–2001
a
Exposure Level
No. of
Exposed
Cases
No. of
Unexposed
Cases
No. of
Exposed
Controls
No. of
Unexposed
Controls
Crude
OR 95% CI Adjusted
OR
b 95% CI
Trend
OR 95% CI
No. of days since ﬁrst
prescription 0.89 0.82, 0.97
0–10 13 2,034 95 19,502 1.35 0.75, 2.44 1.23 0.67, 2.27
11–19 12 2,034 90 19,502 1.35 0.73, 2.49 1.41 0.75, 2.66
20–39 26 2,034 152 19,502 1.53 0.99, 2.36 1.32 0.83, 2.10
40–79 18 2,034 175 19,502 0.95 0.56, 1.59 0.86 0.50, 1.47
80–159 22 2,034 183 19,502 1.15 0.73, 1.81 1.11 0.70, 1.77
 160 191 2,034 2,233 19,502 0.83 0.71, 0.97 0.79 0.67, 0.93
Cumulative dose within past
90 days, no. of tablets 0.95 0.81, 1.10
0–99 19 2,034 143 19,502 1.21 0.73, 1.98 1.12 0.67, 1.87
100–199 126 2,034 1,322 19,502 0.91 0.75, 1.11 0.88 0.72, 1.07
200–299 112 2,034 1,196 19,502 0.92 0.75, 1.13 0.87 0.71, 1.07
300–399 16 2,034 173 19,502 0.91 0.54, 1.52 0.77 0.45, 1.32
 400 9 2,034 94 19,502 0.90 0.45, 1.79 0.84 0.41, 1.69
Lifetime cumulative dose,
no. of tablets 0.93 0.85, 1.01
0–99 8 2,034 60 19,502 1.30 0.62, 2.76 1.16 0.54, 2.52
100–199 46 2,034 364 19,502 1.18 0.85, 1.63 1.08 0.77, 1.51
200–399 57 2,034 559 19,502 0.98 0.74, 1.31 0.91 0.68, 1.22
400–799 56 2,034 638 19,502 0.83 0.62, 1.10 0.80 0.60, 1.06
800–1,599 65 2,034 671 19,502 0.96 0.74, 1.25 0.93 0.71, 1.22
 1,600 50 2,034 636 19,502 0.77 0.57, 1.03 0.74 0.55, 0.99
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a The main composite endpoint was used in all analyses (see Table 2).
b Adjusted for a prior diagnosis of obesity, diabetes, hypertension, ischemic heart disease, chronic obstructive pulmonary disease, cerebral
ischemia, or stroke and for ever use of antidiabetic agents, thiazides, beta-blockers, calcium channel blockers, medications acting on the renin-
angiotensin system, inhaled anticholinergic agents, systemic beta-agonists, and statins. (See text for details.)
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the substance was used for colds or for weight loss (OR ¼
1.2 vs. OR ¼ 15.9), which may suggest some confounding
by obesity. In a substudy exclusively evaluating exposure to
genuine ephedra alkaloids, an overall null ﬁnding was re-
ported (OR ¼ 1.0), with a possible detrimental effect with
large doses (OR ¼ 3.6, 95% CI: 0.7, 18) (18). In a recent
study from South Korea, Yoon et al. (19) reported an asso-
ciation between phenylpronalolamine and stroke, even
when it was used against cold. In a meta-analysis of ran-
domized studies of ephedra alkaloids, no serious cardiovas-
cular events were observed among the subjects, and the
authors were able to conﬁdently exclude event rates above
1 per 1,000 treated persons (1).
A major prerequisite for the case-crossover design is that
the unmeasured confounders are stable over time. Obvi-
ously, smoking behavior or body mass index may change
over a year for an individual. However, stable tobacco ab-
stinence or weight loss is an exception rather a rule (20, 21),
and smokers continue to have a high cardiovascular risk for
some time after having stopped smoking (22), as do persons
who have lost weight (23). Thus, within the time frames of
our study, the individual health effects of smoking and over-
weight were reasonably stable and were unlikely to have
confounded our estimates materially.
For one endpoint, death occurring outside of a health in-
stitution, we observed odds ratios below unity. This should
not be taken too literally as a protective effect. One possible
explanation is that some of these subjects died at home from
chronic nonmalignant diseases that had not resulted in sec-
ondary care contacts. These subjects were obviously very
unlikely to have used ephedrine/caffeine shortly before their
deaths. In addition, some subjects with impending cardio-
vascular events could have been warned by subtle symptoms
and could have chosen to discontinue use of ephedrine for
fear of its claimed toxicity. We performed a subanalysis in
subjects with no prior cardiovascular diagnoses and no prior
use of cardiovascular, antidiabetic, antithrombotic, or anti-
hypertensive agents (Table 3). The estimate for this sub-
group differed very little from the main estimate
(OR ¼ 0.81, 95% CI: 0.61, 1.08; after adjustment for trend,
OR ¼ 0.84, 95% CI: 0.62, 1.14). These ‘‘confounding-by-
contraindication’’ effects are difﬁcult to manage in observa-
tional studies, insofar as the warning symptoms are not
always captured by available data sources, and we cannot
rule out the possibility that the odds ratios for the main
estimates may have been biased downward.
Another limitation is that in our main analysis, we as-
sumed an immediate effect of ephedrine/caffeine. If an ad-
verse effect of ephedrine/caffeine had delayed onset (e.g., if
it were mediated through a hypertensive effect), we might
not have captured it by our crossover analysis. However,
there was nothing in our case-control analysis to suggest
a delayed effect with continuous exposure.
Regarding the possibility of misclassiﬁcation of case or
exposure status, recent validations in our setting have shown
positive predictive values on the order of 95% for both myo-
cardialinfarctionand strokediagnoses (24, 25).Theprescrip-
tion data in our data sources have a high level of accuracy
(26). The main uncertainty regarding exposure was the exact
timing of ephedrine intake relative to the ﬁlling of the pre-
scriptions. Our sensitivity analyses showed the ﬁndings to be
robust within reasonable assumptions about daily intake.
Our results have two major implications. First, we should
not blindly trust the ﬁndings of spontaneous reporting
schemes. Such systems are vulnerable to a ‘‘snowball’’ ef-
fect, whereby products that have acquired a poor reputation
generate new adverse reports. The few controlled clinical
studies that have been conducted—including ours—have
failed to demonstrate any cardiovascular toxicity of ephed-
rine (1, 18). Second, although ephedrine has been banned
from the US market, it is probably available through illicit
channels, through the Internet or as a nondeclared dietary
supplement (27), just as similar products are in free trade in
other parts of the world. Thus, the safety of these com-
pounds is still relevant.
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